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Summary
This report is the first of a two-part statement from the Advisory Committee on Immunization Practices (ACIP) that updates
the strategy to eliminate hepatitis B virus (HBV) transmission in the United States. The report provides updated recommenda-
tions to improve prevention of perinatal and early childhood HBV transmission, including implementation of universal infant
vaccination beginning at birth, and to increase vaccine coverage among previously unvaccinated children and adolescents. Strat-
egies to enhance implementation of the recommendations include 1) establishing standing orders for administration of hepatitis B
vaccination beginning at birth; 2) instituting delivery hospital policies and procedures and case management programs to im-
prove identification of and administration of immunoprophylaxis to infants born to mothers who are hepatitis B surface antigen
(HBsAg) positive and to mothers with unknown HBsAg status at the time of delivery; and 3) implementing vaccination record
reviews for all children aged 11–12 years and children and adolescents aged <19 years who were born in countries with interme-
diate and high levels of HBV endemicity, adopting hepatitis B vaccine requirements for school entry, and integrating hepatitis B
vaccination services into settings that serve adolescents. The second part of the ACIP statement, which will include updated
recommendations and strategies to increase hepatitis B vaccination of adults, will be published separately.
Hepatitis B vaccination is the most effective measure to pre-
vent HBV infection and its consequences. Since they were
first issued in 1982, recommendations for hepatitis B vacci-
nation have evolved into a comprehensive strategy to elimi-
nate HBV transmission in the United States (2–6) (Box 1). A
primary focus of this strategy is universal vaccination of
infants to prevent early childhood HBV infection and to even-
tually protect adolescents and adults from infection. Other
components include routine screening of all pregnant women
for hepatitis B surface antigen (HBsAg) and postexposure
immunoprophylaxis of infants born to HBsAg-positive
women, vaccination of children and adolescents who were not
previously vaccinated, and vaccination of unvaccinated adults
at increased risk for infection.
To date, the immunization strategy has been implemented
with considerable success. Recent estimates indicate that >95%
of pregnant women are tested for HBsAg, and case manage-
ment has been effective in ensuring high levels of initiation
and completion of postexposure immunoprophylaxis among
identified infants born to HBsAg-positive women (7). Hepa-
titis B vaccine has been successfully integrated into the child-
hood vaccine schedule, and infant vaccine coverage levels are
now equivalent to those of other vaccines in the childhood
schedule. During 1990–2004, incidence of acute hepatitis B
Strategy to Eliminate Hepatitis B
Virus Transmission
 Hepatitis B virus (HBV) is a bloodborne and sexually trans-
mitted virus. Rates of new infection and acute disease are high-
est among adults, but chronic infection is more likely to occur
in persons infected as infants or young children. Before hepa-
titis B vaccination programs became routine in the United
States, an estimated 30%–40% of chronic infections are
believed to have resulted from perinatal or early childhood
transmission, even though <10% of reported cases of hepati-
tis B occurred in children aged <10 years (1). Chronically
infected persons are at increased lifetime risk for cirrhosis and
hepatocellular carcinoma (HCC) and also serve as the main
reservoir for continued HBV transmission.
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in the United States declined 75%. The greatest decline (94%)
occurred among children and adolescents, coincident with an
increase in hepatitis B vaccine coverage. As of 2004, among
U.S. children aged 19–35 months, >92% had been fully vac-
cinated with 3 doses of hepatitis B vaccine (8). This success
can be attributed in part to the established infrastructure for
vaccine delivery to children and to federal support for perina-
tal hepatitis B prevention programs.
Vaccine coverage among adolescents has also increased sub-
stantially. Preliminary data demonstrate that 50%–60% of
adolescents aged 13–15 years have records indicating vacci-
nation (with 3 doses) against hepatitis B (CDC, unpublished
data, 2003). As of November 2005, a total of 34 states require
vaccination for middle-school entry (9). Certain programs
provide hepatitis B vaccine to youth who engage in behaviors
that place them at high risk for HBV infection (i.e., injection-
drug use, having more than one sex partner, and male sexual
activity with other males), and adolescent hepatitis B vaccina-
tion is included as a Health Plan Employer Data Information
Set (HEDIS) measure (10).
Despite these successes, challenges remain. Even with
improvements in the management of pregnant women, only
approximately 50% of expected births to HBsAg-positive
women are identified (on the basis of application of racial/
ethnic-specific HBsAg prevalence estimates to U.S. natality
data) for case management, which maximizes timely delivery
of postexposure immunoprophylaxis (11; CDC, unpublished
data, 2004). The need for proper management of women with-
out prenatal care, including HBsAg testing at the time of ad-
mission for delivery and administration of the first dose of
vaccine to infants <12 hours of birth, is underscored by the
higher prevalence of HBsAg seropositivity among these women
than among women who are screened prenatally (12). Even
when maternal HBsAg testing does occur, certain infants of
HBsAg-positive mothers do not receive postexposure immuno-
prophylaxis because of testing errors and lapses in reporting
of test results (13), and infants of women with unknown
HBsAg status at the time of delivery often do not receive a
birth dose of vaccine (14). Birth dose coverage in 2004 was
only 46% (National Immunization Survey, unpublished data,
2004), and coverage has not returned to levels from before
July 1999 (54%), when recommendations were made to tem-
porarily suspend administration of hepatitis B vaccines at birth
until vaccines that do not contain thimerosal as a preservative
became available (15). Among adolescents, efforts to prevent
HBV transmission are hampered by the low rate of health-
care visits in this age group compared with that of young chil-
dren and the frequency of initiation of high-risk behaviors.
To address these remaining challenges and accelerate progress
toward elimination of HBV transmission in the United States,
the ACIP has updated the hepatitis B immunization recom-
mendations for infants, children, and adolescents and supple-
mented the recommendations with strategies for
implementation. The recommendations and implementation
strategies address prevention of perinatal and early childhood
transmission and routine vaccination of children and adoles-
cents. A main focus is on universal infant vaccination begin-
ning at birth, which provides a “safety net” for prevention of
perinatal infection, prevents early childhood infections, facili-
tates implementation of universal vaccination recommendations,
and prevents infections in adolescents and adults. The second
part of the ACIP statement, which includes updated recom-
mendations and implementation strategies to increase hepatitis




This report provides updated recommendations and
approaches to address challenges in implementing the strat-
egy to eliminate HBV transmission in the United States. These
include the following measures:
• Improve prevention of perinatal and early childhood
HBV transmission. Implement delivery hospital policies
and procedures, case-management programs, and laws and
regulations to improve identification of infants born to
HBsAg-positive mothers and to mothers with unknown
HBsAg status at the time of delivery, ensure administra-
tion of appropriate postexposure immunoprophylaxis to
these infants beginning at birth, and administer a birth
dose of hepatitis B vaccine to medically stable infants who
weigh >2,000 g and who are born to HBsAg-negative
mothers.
BOX 1. Immunization strategy to eliminate transmission of
hepatitis B virus (HBV) infection in the United States
• Universal vaccination of infants beginning at birth
• Prevention of perinatal HBV infection through
— routine screening of all pregnant women for hepa-
titis B surface antigen (HBsAg), and
— immunoprophylaxis of infants born to HBsAg-
positive women and infants born to women with
unknown HBsAg status
• Routine vaccination of previously unvaccinated children
and adolescents
• Vaccination of previously unvaccinated adults at
increased risk for infection
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• Improve vaccine coverage of children and adolescents
who were not previously vaccinated. Implement immu-
nization record reviews for all children aged 11–12 years
and children and adolescents aged <19 years who were
born in countries in which HBV endemicity is high or
intermediate (Figure 1 and Box 2); adopt hepatitis B vac-
cine requirements for school entry; and vaccinate all un-
vaccinated adolescents in settings that provide health-care
services to persons in this age group.
Background
Clinical Features and Natural
History of HBV Infection
HBV is a 42-nm DNA virus classified in the Hepadnaviridae
family. The liver is the primary site of HBV replication. After
a susceptible person is exposed, the virus enters the liver via
the bloodstream; no evidence exists indicating that the virus
replicates at mucosal surfaces. HBV infection can produce
either asymptomatic or symptomatic infection. The average
incubation period is 90 days (range: 60–150 days) from
exposure to onset of jaundice and 60 days (range: 40–90 days)
from exposure to onset of abnormal serum alanine aminotrans-
ferase (ALT) levels (17,18).
The onset of acute disease is usually insidious. Infants and
young children (aged <10 years) are typically asymptomatic
(19). When present, clinical symptoms and signs might
include anorexia, malaise, nausea, vomiting, abdominal pain,
and jaundice. Extrahepatic manifestations of disease (e.g., skin
rashes, arthralgias, and arthritis) also can occur (20). The
fatality rate among persons with reported acute hepatitis B is
0.5%–1.5%, with highest rates in adults aged >60 years (21).
Although the consequences of acute hepatitis B can be severe,
the majority of serious sequelae associated with HBV disease
occur in persons who are chronically infected. Persons with
chronic infection also serve as the major reservoir for contin-
ued HBV transmission. Chronic infection occurs in approxi-
mately 90% of infected infants, 30% of infected children aged
<5 years, and <5% of infected persons aged >5 years, with
continuing viral replication in the liver and persistent viremia





* For multiple countries, estimates of prevalence of hepatitis B surface antigen (HBsAg), a marker of chronic HBV infection, are based on limited data and
might not reflect current prevalence in countries that have implemented routine childhood hepatitis B vaccination. In addition, HBsAg prevalence rates
might vary within countries by subpopulation and locality.
FIGURE 1. Geographic distribution of chronic hepatitis B virus (HBV) infection, 2005*
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quently in immunosuppressed persons (e.g., hemodialysis
patients and persons with human immunodeficiency virus
[HIV] infection) (23,25,26). On the basis of data from fol-
low-up studies of persons infected with HBV as infants or
young children, approximately 25% of those with chronic
infection die prematurely from cirrhosis or liver cancer; the
majority remain asymptomatic until onset of cirrhosis or end-
stage liver disease (27–29).
No specific treatment exists for acute hepatitis B. Persons
who have chronic HBV infection require medical evaluation
and regular monitoring (30,31). Therapeutic agents approved
by the Food and Drug Administration (FDA) for treatment
of chronic hepatitis B can achieve sustained suppression of
HBV replication and remission of liver disease in certain per-
sons (31). Periodic screening with alfa fetoprotein or imaging
studies has been demonstrated to enhance early detection of
HCC (31). Chronically infected persons with HCC have been
reported to have experienced long-term survival after resec-
tion or ablation of small HCCs, and persons who were screened
had a substantial survival advantage compared with historic
controls (31).
Reinfection or reactivation of latent HBV infection has been
reported among certain groups of immunosuppressed persons,
including renal transplant recipients, HIV-infected patients,
bone marrow transplant recipients, and patients receiving che-
motherapy (32–35). The frequency with which this phenom-
enon occurs is unknown.
Interpretation of Serologic Markers
of HBV Infection
The antigens and antibodies associated with HBV infec-
tion include HBsAg and antibody to HBsAg (anti-HBs), hepa-
titis B core antigen (HBcAg) and antibody to HBcAg
(anti-HBc), and hepatitis B e antigen (HBeAg) and antibody
to HBeAg (anti-HBe). At least one serologic marker is present
during the different phases of HBV infection (Table 1) (18,36).
Serologic assays are commercially available for all markers
except HBcAg because no free HBcAg circulates in blood.
The presence of a confirmed HBsAg result is indicative of
ongoing HBV infection. All HBsAg-positive persons should
be considered infectious. In newly infected persons, HBsAg is
the only serologic marker detected during the first 3–5 weeks
after infection, and it persists for variable periods at very low
levels. The average time from exposure to detection of HBsAg
is 30 days (range: 6–60 days) (17,18). Highly sensitive single-
TABLE 1. Typical interpretation of serologic test results for
hepatitis B virus infection
                 Serologic marker
Total IgM§
anti- anti- Anti-
HBsAg* HBc† HBc HBs¶ Interpretation
–** – – – Never infected
+††§§ – – – Early acute infection; transient
(up to 18 days) after vaccination
+ + + – Acute infection
– + + – Acute resolving infection
– + – + Recovered from past infection and
immune
+ + – – Chronic infection
– + – – False positive (i.e., susceptible);
past infection; “low-level” chronic
infection;¶¶ passive transfer to infant
born to HBsAg-positive mother
– – – + Immune if concentration is
>10 mIU/mL,*** passive transfer
after hepatitis B immune globulin
administration
* Hepatitis B surface antigen.
† Antibody to hepatitis B core antigen.
§ Immunoglobulin M.
¶ Antibody to HBsAg.
** Negative test result.
†† Positive test result.
§§ To ensure that an HBsAg-positive test result is not a false positive,
samples with repeatedly reactive HBsAg results should be tested with a
licensed (and, if appropriate, neutralizing confirmatory) test.
¶¶ Persons positive for only anti-HBc are unlikely to be infectious except
under circumstances in which they are the source for direct percutane-
ous exposure of susceptible recipients to large quantities of virus (e.g.,
blood transfusion or organ transplant).
*** Milli-International Units per milliliter.
BOX 2. Geographic areas with intermediate* and high†
hepatitis B virus endemicity
Africa: all countries
South Asia: all countries except Sri Lanka
Western Pacific: all countries and territories except Aus-
tralia and New Zealand
Middle East: all countries except Cyprus
Eastern Europe: all countries except Hungary
Newly Independent States of the former Soviet Union: all
countries
Western Europe: Greece, Italy, Malta, Portugal, and Spain
North America: Alaska Natives and indigenous popula-
tions of Northern Canada and Greenland
Central America: Belize, Guatemala, Honduras, and
Panama
South America: Argentina, Bolivia, Brazil, Ecuador,
Guyana, Suriname, Venezuela, and the Amazonian
areas of Colombia and Peru
Caribbean: Antigua and Barbuda, Dominica, Dominican
Republic, Grenada, Haiti, Jamaica, Puerto Rico, St. Kitts
and Nevis, St. Lucia, St. Vincent and Grenadines,
Trinidad and Tobago, and Turcs and Caicos
* Hepatitis B surface antigen (HBsAg) prevalence of 2%–7%.
† HBsAg prevalence of >8%.
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sample nucleic acid tests can detect HBV DNA in the serum
of an infected person 10–20 days before detection of HBsAg
(37). Transient HBsAg positivity has been reported for up to
18 days after vaccination and is clinically insignificant (38,39).
Anti-HBc appears at the onset of symptoms or liver test
abnormalities in acute HBV infection and persists for life.
Acute or recently acquired infection can be distinguished by
the presence of the IgM class of anti-HBc, which is detected
at the onset of acute hepatitis B and persists for up to 6 months
if the disease resolves. In patients who develop chronic hepa-
titis B, IgM anti-HBc can persist at low levels during viral
replication and can result in positive tests for IgM anti-HBc
(40). In addition, false-positive IgM anti-HBc test results can
occur. Because the positive predictive value is low in asymp-
tomatic persons, for diagnosis of acute hepatitis B, testing for
IgM anti-HBc should be limited to persons with clinical evi-
dence of acute hepatitis or an epidemiologic link to a case.
In persons who recover from HBV infection, HBsAg is elimi-
nated from the blood, usually within 3–4 months, and anti-
HBs develops during convalescence. The presence of anti-HBs
typically indicates immunity from HBV infection. Infection
or immunization with one genotype of HBV confers immu-
nity to all genotypes. In addition, anti-HBs can be detected
for several months after hepatitis B immune globulin (HBIG)
administration. The majority of persons who recover from
natural infection will be positive for both anti-HBs and anti-
HBc, whereas persons who respond to hepatitis B vaccine have
only anti-HBs. In persons who become chronically infected,
HBsAg and anti-HBc persist, typically for life. HBsAg will
become undetectable in approximately 0.5%–2% of chroni-
cally infected persons yearly, and anti-HBs will occur in the
majority of these persons (41–44).
In certain persons, the only HBV serologic marker detected
in serum is anti-HBc. Isolated anti-HBc can occur after HBV
infection among persons who have recovered but whose anti-
HBs levels have waned or among persons in whom anti-HBs
failed to occur. Persons in the latter category include those
with circulating HBsAg levels not detectable by commercial
assays. These persons are unlikely to be infectious except
under circumstances in which they are the source for direct
percutaneous exposure of susceptible recipients to substantial
quantities of virus (e.g., through blood transfusion or follow-
ing liver transplantation) (45). HBV DNA has been detected
in the blood of <5% of persons with isolated anti-HBc (46).
Typically, the frequency of isolated anti-HBc relates directly
to the prevalence of HBV infection in the population. In popu-
lations with a high prevalence of HBV infection, isolated anti-
HBc likely indicates previous infection, with loss of anti-HBs.
For persons in populations with a low prevalence of HBV
infection, an isolated anti-HBc result often represents a false-
positive reaction. The majority of these persons have a pri-
mary anti-HBs response after a 3-dose series of hepatitis B
vaccine (47,48). Infants who are born to HBsAg-positive
mothers and who do not become infected might have detect-
able anti-HBc for <24 months after birth from passively trans-
ferred maternal antibody.
HBeAg can be detected in the serum of persons with acute
or chronic HBV infection. The presence of HBeAg correlates
with viral replication and high levels of virus (i.e., high infec-
tivity) (49,50). Anti-HBe correlates with the loss of replicat-
ing virus and with lower levels of virus, although reversion to
HBeAg positivity has been observed (44).
Epidemiology of HBV Infection
Transmission
HBV is transmitted by percutaneous (i.e., puncture through
the skin) or mucosal (i.e., direct contact with mucous mem-
branes) exposure to infectious blood or to body fluids that
contain blood. All HBsAg-positive persons are infectious, but
those who are also HBeAg positive are more infectious
because their blood contains high titers of HBV (typically 107–
109 virions/mL) (49,50). Although HBsAg has been detected
in multiple body fluids, only serum, semen, and saliva have
been demonstrated to be infectious (51,52). HBV is com-
paratively stable in the environment and remains viable for
>7 days on environmental surfaces at room temperature (53).
HBV at concentrations of 102–3 virions/mL can be present
on environmental surfaces in the absence of any visible blood
and still cause transmission (53,54).
For infants and children, the two primary sources of HBV
infection are perinatal transmission from infected mothers and
horizontal transmission from infected household contacts.
Adolescents are at risk for HBV infection primarily through
high-risk sexual activity (i.e., sex with more than one partner
and male sexual activity with other males) and injection-drug
use (21). Transmission of HBV via transfusion of blood and
plasma-derived products is rare because of donor screening
for HBsAg and viral inactivation procedures.
For a newborn infant whose mother is positive for both
HBsAg and HBeAg, the risk for chronic HBV infection is
70%–90% by age 6 months in the absence of postexposure
immunoprophylaxis (55–57). For infants of women who are
HBsAg positive but HBeAg negative, the risk for chronic
infection is <10% in the absence of postexposure immuno-
prophylaxis (58–60). Rare cases of fulminant hepatitis B
among perinatally infected infants also have been reported
(61,62). Studies suggest that breastfeeding by an HBsAg-
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positive mother does not increase the risk for acquisition of
HBV infection in the infant (63).
Children who are not infected at birth remain at risk from
long-term interpersonal contact with their infected mothers.
In one study, 38% of infants who were born to HBsAg-
positive mothers and who were not infected perinatally
became infected by age 4 years (64). In addition, children
living with any chronically infected persons are at risk for
becoming infected through percutaneous or mucosal expo-
sures to blood or infectious body fluids (e.g., sharing a tooth-
brush, contact with exudates from dermatologic lesions,
contact with HBsAg-contaminated surfaces). HBV transmis-
sion rates to susceptible household contacts of chronically
infected persons have varied (range: 14%–60%) (65,66). High
rates of infection also have been reported among unvaccinated
long-term residents of institutions for the mentally handi-
capped (67,68), and, in rare instances, person-to-person trans-
mission has been reported in child care settings (69,70).
Incidence
During 1990–2004, overall incidence of reported acute
hepatitis B declined 75%, from 8.5 to 2.1 per 100,000 popu-
lation. The most dramatic declines occurred in the cohort of
children to whom recommendations for routine infant and
adolescent vaccination have applied. Incidence among chil-
dren aged <12 years and adolescents aged 12–19 years
declined 94%, from 1.1 to 0.36 and 6.1 to 2.8 per 100,000
population, respectively (Figure 2). Since implementation of
routine childhood immunization, an estimated 6,800 perina-
tal infections and an additional 18,700 infections during the
first 10 years of life have been prevented annually in the United
States (71).
Although infections in infants and children aged <10 years
represented <10% of all HBV infections before implementa-
tion of childhood immunization programs, childhood infec-
tions resulted in an estimated 30%–40% of the chronic HBV
infections among persons who acquired their infections in the
United States (1). In two population-based studies conducted
among Asian/Pacific Islander children who were born in the
United States before perinatal hepatitis B prevention programs
were widely implemented, 61%–66% of the chronic HBV
infections occurred in children born to HBsAg-negative moth-
ers (72,73). A substantial proportion of these chronic infec-
tions would not have been prevented by a selective program
of identification and immunization of only infants born to
HBsAg-positive mothers.
In addition to declines in incidence among all age groups,
racial disparities in hepatitis B incidence among children have
been substantially reduced (Figure 3). The reduction of the
disparity between Asian/Pacific Islander and other children is
consistent with recent observations noting a decline in
seroprevalence of HBV infection after successful implemen-
tation of routine hepatitis B vaccination among Asians who
have recently immigrated to the United States (74,75). How-
ever, as hepatitis B incidence has declined among U.S.-born
children, unvaccinated foreign-born children account for a
high proportion of infections. During 2001–2002, of 19 chil-
dren born after 1991 in whom acute hepatitis B had been
verified, eight (42%) were foreign born (76).
Prevalence
In the U.S. population, the overall age-adjusted prevalence
of HBV infection (including persons with chronic infection
and those with previous infection) was 4.9% in the third
* Per 100,000 population.
FIGURE 2.  Reported acute hepatitis B incidence,* by age group









































FIGURE 3. Reported acute hepatitis B incidence* among
persons aged <19 years, by race/ethnicity and year — United
States, 1990–2004
* Per 100,000 population.
† Asian/Pacific Islander.
§ American Indian/Alaska Native.
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National Health and Nutrition Examination Survey
(NHANES III, 1988–1994) (77). Foreign-born persons (par-
ticularly Asian/Pacific Islanders) who have emigrated from
countries in which HBV is endemic (Figure 1 and Box 2)
contribute disproportionately to the burden of chronic HBV
infection in the United States. The prevalence of chronic HBV
infection among foreign-born persons immigrating to the
United States from Central and Southeast Asia, the Middle
East, and Africa varies (range: 5%–15%) and reflects the pat-
terns of HBV infection in the countries and regions of origin
for these persons. During 1994–2003, approximately 40,000
immigrants with chronic HBV infection were admitted
annually to the United States for permanent residence (78;
CDC, unpublished data, 2005).
Prophylaxis Against HBV Infection
Hepatitis B Vaccine
HBsAg is the antigen used for hepatitis B vaccination
(79,80). Vaccine antigen can be purified from the plasma of
persons with chronic HBV infection or produced by recom-
binant DNA technology. Vaccines available in the United States
use recombinant DNA technology to express HBsAg in yeast,
which is then purified from the cells by biochemical and bio-
physical separation techniques (81,82). Hepatitis B vaccines
licensed in the United States are formulated to contain
10–40 µg of HBsAg protein/mL. Since March 2000, hepati-
tis B vaccines produced for distribution in the United States
do not contain thimerosal as a preservative or contain only a
trace amount (<1.0 mcg mercury/mL) from the manufactur-
ing process (83,84).
Hepatitis B vaccine is available as a single-antigen formula-
tion and also in fixed combination with other vaccines. Two
single-antigen vaccines are available in the United States:
Recombivax HB® (Merck & Co., Inc., Whitehouse Station,
New Jersey) and Engerix-B® (GlaxoSmithKline Biologicals,
Rixensart, Belgium). Of the three licensed combination vac-
cines, one (Twinrix® [GlaxoSmithKline Biologicals, Rixensart,
Belgium]) is used for vaccination of adults, and two (Comvax®
[Merck & Co., Inc., Whitehouse Station, New Jersey] and
Pediarix® [GlaxoSmithKline Biologicals, Rixensart, Belgium])
are used for vaccination of infants and young children. Twinrix
contains recombinant HBsAg and inactivated hepatitis A virus.
Comvax contains recombinant HBsAg and Haemophilus
influenzae type b (Hib) polyribosylribitol phosphate conju-
gated to Neisseria meningitidis outer membrane protein com-
plex. Pediarix contains recombinant HBsAg, diphtheria and
tetanus toxoids and acellular pertussis adsorbed (DTaP), and
inactivated poliovirus (IPV).
HBIG
HBIG provides passively acquired anti-HBs and temporary
protection (i.e., 3–6 months) when administered in standard
doses. HBIG is typically used as an adjunct to hepatitis B
vaccine for postexposure immunoprophylaxis to prevent HBV
infection. HBIG administered alone is the primary means of
protection after an HBV exposure for nonresponders to hepa-
titis B vaccination.
HBIG is prepared from the plasma of donors with high
concentrations of anti-HBs. The plasma is screened to elimi-
nate donors who are positive for HBsAg, antibodies to HIV
and hepatitis C virus (HCV), and HCV RNA. In addition,
proper manufacturing techniques for HBIG inactivate viruses
(e.g., HBV, HCV, and HIV) from the final product (85,86).
No evidence exists that HBV, HCV, or HIV ever has been
transmitted by HBIG commercially available in the United
States. HBIG that is commercially available in the United
States does not contain thimerosal.
Vaccination Schedules
and Results of Vaccination
Preexposure Vaccination
Infants and Children
Primary vaccination consists of >3 intramuscular doses of
hepatitis B vaccine (Table 2). Vaccine schedules for infants
and children (Tables 3–5) are determined on the basis of
immunogenicity data and the need to integrate hepatitis B
vaccine into a harmonized childhood vaccination schedule.
Although not all possible schedules for each product have been
evaluated in clinical trials, available licensed formulations for
both single-antigen vaccines produce high (>95%) levels of
seroprotection among infants and children when
administered in multiple schedules (87–91).
The immunogenicity of the combined hepatitis B-Hib con-
jugate vaccine (Comvax) and the combined hepatitis B-DTaP-
IPV vaccine (Pediarix) is equivalent to that of their individual
antigens administered separately. However, these vaccines can-
not be administered to infants aged <6 weeks; only single-
antigen hepatitis B vaccine may be used for the birth dose.
Use of 4-dose hepatitis B vaccine schedules, including sched-
ules with a birth dose, has not increased vaccine reactogenicity
(92,93). Anti-HBs responses after a 3-dose series of hepatitis
B-containing combination vaccines among infants who were
previously vaccinated at birth with single-antigen hepatitis B
vaccine are comparable to those observed after a 3-dose series
of combination vaccine without a birth dose (93).
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Birth Dose
Hepatitis B vaccine can be administered soon after birth
with only minimal decrease in immunogenicity, compared with
administration at older ages, and no decrease in protective
efficacy (87). Administration of a birth dose of hepatitis B
vaccine is required for effective postexposure immuno-
prophylaxis to prevent perinatal HBV infection. Although
infants who require postexposure immunoprophylaxis should
be identified by maternal HBsAg testing, administering a birth
dose to infants even without HBIG serves as a “safety net” to
prevent perinatal infection among infants born to HBsAg-
positive mothers who are not identified because of errors in
maternal HBsAg testing or failures in reporting of test results
(13). The birth dose also provides early protection to infants
at risk for infection after the perinatal period. Administration
of a birth dose has been associated with higher rates of
on-time completion of the hepatitis B vaccine series (15,94).
In certain populations, the birth dose has been associated with
improved completion rates for all other infant vaccines (95),
although findings have not been consistent (15,94).
Adolescents
Recommended vaccination schedules for adolescents bal-
ance available immunogenicity data with the need to achieve
compliance with vaccination in this age group (Tables 2 and
5). Both licensed single-antigen hepatitis B vaccines adminis-
tered intramuscularly at 0, 1, and 6 months produce a >95%
sero-protection rate in adolescents. Equivalent seroprotection
rates are achieved among adolescents vaccinated at 0, 1–2,
and 4 months and 0, 12, and 24 months. The adult (10 µg)
dose of Recombivax-HB administered in a 2-dose schedule to
children and adolescents aged 11–15 years at 0 and 4–6 months
produces antibody levels equivalent to those obtained with
the 5-µg dose administered on a 3-dose schedule (96,97).
However, no data on long-term antibody persistence or pro-
tection are available for 2-dose schedules. No combination
vaccines containing hepatitis B vaccine antigen are approved
for use in adolescents aged 11–17 years.
Nonstandard Vaccine Schedules
No apparent effect on immunogenicity has been documented
when minimum spacing of doses is not achieved precisely.
Increasing the interval between the first 2 doses has little effect
on immunogenicity or final antibody concentration (98–100).
The third dose confers the maximum level of seroprotection
but acts primarily as a booster and appears to provide optimal
long-term protection (101). Longer intervals between the last 2
doses result in higher final antibody levels but might increase
the risk for acquisition of HBV infection among persons who
have a delayed response to vaccination. No differences in
immunogenicity have been observed when 1 or 2 doses of hepa-
titis B vaccine produced by one manufacturer are followed by
doses from a different manufacturer (102).
TABLE 2. Recommended doses of currently licensed formulations of hepatitis B vaccine, by age group and vaccine type
Single-antigen vaccine Combination vaccine
Recombivax HB Engerix-B Comvax* Pediarix† Twinrix§
Dose Volume Dose Volume Dose Volume Dose Volume Dose Volume
Age group (µg)¶ (mL) (µg)¶ (mL) (µg)¶ (mL) (µg)¶ (mL) (µg)¶ (mL)
Infants (<1 yr) 5 0.5 10 0.5 5 0.5 0 0.5 NA** NA
Children (1–10 yrs) 5 0.5 10 0.5 5* 0.5 10† 0.5 NA NA
Adolescents
11–15 yrs 10†† 1.0 NA NA NA NA NA NA NA NA
11–19 yrs 5 0.5 10 0.5 NA NA NA NA NA NA
Adults (>20 yrs) 10 1.0 20 1.0 NA NA NA NA 20§ 1.0
Hemodialysis patients and other
immunocompromised persons
<20 yrs§§ 5 0.5 10 0.5 NA NA NA NA NA NA
>20 yrs 40¶¶ 1.0 40*** 2.0 NA NA NA NA NA NA
* Combined hepatitis B–Haemophilus influenzae type b conjugate vaccine. This vaccine cannot be administered at birth, before age 6 weeks, or after age 71
months.
† Combined hepatitis B–diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine. This vaccine cannot be administered at birth, before age
6 weeks, or at age >7 years.
§ Combined hepatitis A and hepatitis B vaccine. This vaccine is recommended for persons aged >18 years who are at increased risk for both hepatitis B virus
and hepatitis A virus infections.
¶ Recombinant hepatitis B surface antigen protein dose.
** Not applicable.
†† Adult formulation administered on a 2-dose schedule.
§§ Higher doses might be more immunogenic, but no specific recommendations have been made.
¶¶ Dialysis formulation administered on a 3-dose schedule at age 0, 1, and 6 months.
*** Two 1.0-mL doses administered at one site, on a 4-dose schedule at age 0, 1, 2, and 6 months.
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Response to Revaccination
A study of infants born to HBsAg-positive mothers
who did not respond to a primary vaccine series indi-
cated that all those not infected with HBV responded
satisfactorily to a repeat 3-dose revaccination series (103).
No data suggest that children who have no detectable
antibody after 6 doses of vaccine would benefit from
additional doses.
Groups Requiring Different Vaccination
Doses or Schedules
Preterm infants. Preterm infants weighing <2,000 g
at birth have a decreased response to hepatitis B vaccine
administered before age 1 month (104–106). By age 1
month, medically stable preterm infants, regardless of
initial birth weight or gestational age, have a response
to vaccination that is comparable to that of full-term
infants (107–110).
Hemodialysis patients and other immunoco-
mpromised persons. Although data concerning the
response of pediatric hemodialysis patients to vaccina-
tion with standard pediatric doses are lacking, protec-
tive levels of antibody occur in 75%–97% of those who
receive higher dosages (20-µg) on either the 3- or the
4-dose schedule (111–114). Humoral response to hepa-
titis B vaccination is also reduced in other children and
adolescents who are immunocompromised (e.g.,
hematopoietic stem cell transplant recipients, patients
undergoing chemotherapy, and HIV-infected persons)
(115–119). Modified dosing regimens, including a dou-
bling of the standard antigen dose or administration of
additional doses, might increase response rates (120).
However, data on response to these alternative vaccina-
tion schedules are limited (121).
Immune Memory
Anti-HBs is the only easily measurable correlate of vac-
cine-induced protection. Immunocompetent persons who
achieve anti-HBs concentrations >10 mIU/mL after
preexposure vaccination have virtually complete protec-
tion against both acute disease and chronic infection even
if anti HBs concentrations subsequently decline to <10
mIU/mL (122–125). Although immunogenicity is lower
among immunocompromised persons, those who achieve
and maintain a protective antibody response before
exposure to HBV have a high level of protection from
infection.
After primary immunization with hepatitis B vaccine,
anti-HBs concentrations decline rapidly within the first
TABLE 3. Hepatitis B vaccine schedules for newborn infants, by
maternal hepatitis B surface antigen (HBsAg) status*
Maternal Single antigen +
 HBsAg Single-antigen vaccine combination vaccine
status Dose Age Dose Age
Positive 1† Birth (<12 hrs) 1† Birth (<12 hrs)
HBIG§ Birth (<12 hrs) HBIG Birth (<12 hrs)
2 1–2 mos 2 2 mos
3¶ 6 mos 3 4 mos
4¶ 6 mos (Pediarix) or
12–15 mos (Comvax)
Unknown** 1† Birth (<12 hrs) 1† Birth (<12 hrs)
2 1–2 mos 2 2 mos
3¶ 6 mos 3 4 mos
4¶ 6 mos (Pediarix) or
12–15 mos (Comvax)
Negative 1†,†† Birth (before 1†,†† Birth (before discharge)
discharge)
2 1–2 mos 2 2 mos
3¶ 6–18 mos 3 4 mos
4¶ 6 mos (Pediarix) or
12–15 mos (Comvax)
* See Table 4 for vaccine schedules for preterm infants weighing <2,000 g.
† Recombivax HB or Engerix-B should be used for the birth dose. Comvax and
Pediarix cannot be administered at birth or before age 6 weeks.
§ Hepatitis B immune globulin (0.5 mL) administered intramuscularly in a sepa-
rate site from vaccine.
¶ The final dose in the vaccine series should not be administered before age 24
weeks (164 days).
** Mothers should have blood drawn and tested for HBsAg as soon as possible
after admission for delivery; if the mother is found to be HBsAg positive, the
infant should receive HBIG as soon as possible but no later than age 7 days.
†† On a case-by-case basis and only in rare circumstances, the first dose may be
delayed until after hospital discharge for an infant who weighs >2,000 g and
whose mother is HBsAg negative, but only if a physician’s order to withhold the
birth dose and a copy of the mother’s original HBsAg-negative laboratory report
are documented in the infant’s medical record.
TABLE 4. Hepatitis B immunization management of preterm infants





Positive • HBIG* + hepatitis B vaccine (<12 hrs of birth)
• Continue vaccine series beginning at age 1–2 mos
according to recommended schedule for infants born
to HBsAg-positive mothers (see Table 3).
• Do not count birth dose as part of the vaccine series.
• Test for HBsAg and antibody to HBsAg after completion of the
vaccine series at age 9–18 mos (i.e., next well-child visit).
Unknown • HBIG + hepatitis B vaccine (<12 hrs of birth)
• Test mother for HBsAg.
• Continue vaccine series beginning at age 1–2 mos
according to recommended schedule based on the mother’s
HBsAg result (see Table 3).
• Do not count birth dose as part of the vaccine series.
Negative • Delay first dose of hepatitis B vaccine until age 1 mo or hospital
discharge.
• Complete the vaccine series (see Table 3).
* Hepatitis B immune globulin.
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year and more slowly thereafter. Among children who respond
to a primary vaccine series with antibody levels >10 mIU/mL,
15%–50% have low or undetectable concentrations of anti-
HBs (anti-HBs loss) 5–15 years after vaccination (126–130).
The persistence of detectable anti-HBs after vaccination, in
the absence of exposure to HBV, depends on the level of post-
vaccination antibody concentration.
Despite declines in anti-HBs to <10 mIU/mL, nearly all
vaccinated persons are still protected against HBV infection.
The mechanism for continued vaccine-induced protection is
thought to be the preservation of immune memory through
selective expansion and differentiation of clones of antigen-
specific B and T lymphocytes (131). Persistence of vaccine-
induced immune memory among persons who responded to
a primary childhood vaccine series 13–23 years earlier but
then had levels of anti-HBs below 10 mIU/mL has been dem-
onstrated by an anamnestic increase in anti-HBs levels in 67%–
76% of these persons 2–4 weeks after administration of an
additional vaccine dose (132,133). Although direct measure-
ment of immune memory is not yet possible, these data indi-
cate that a high proportion of vaccine recipients retain immune
memory and would develop an anti-HBs response upon ex-
posure to HBV.
Studies of cohorts of immunocompetent persons vaccinated
as children or infants also indicate that, despite anti-HBs loss
years after immunization, nearly all vaccinated persons who
respond to a primary series remain protected from HBV
infection. No clinical cases of hepatitis B have been observed
in follow-up studies conducted 15–20 years after vaccination
among immunocompetent vaccinated persons with antibody
levels >10 mIU/mL. Certain studies have documented break-
through infections (detected by the presence of anti-HBc or
HBV DNA) in a limited percentage of vaccinated persons
(130,131), but these infections are usually transient and
asymptomatic; chronic infections have been documented only
rarely (134). Breakthrough infections resulting in chronic
infection have been observed only among vaccinated infants
born to HBsAg-positive women.
Limited data are available on the duration of immune
memory after hepatitis B vaccination in immunocompromised
persons (e.g., HIV-infected patients, dialysis patients, patients
undergoing chemotherapy, or hematopoietic stem cell trans-
plant patients). No clinically important HBV infections have
been documented among immunocompromised persons who
maintain protective levels of anti-HBs. In studies of long-term
protection among HIV-infected persons, breakthrough infec-
tions occurring after a decline in anti-HBs concentrations to
<10 mIU/mL have been transient and asymptomatic (135).
However, among hemodialysis patients who respond to the
vaccine, clinically significant HBV infection has been docu-
mented in persons who have not maintained anti-HBs con-
centrations of >10 mIU/mL (136).
Postexposure Prophylaxis
Both passive-active postexposure prophylaxis (PEP) with
HBIG and hepatitis B vaccine and active PEP with hepatitis
B vaccine alone have been demonstrated to be highly effective
in preventing transmission after exposure to HBV (137–140).
HBIG alone has also been demonstrated to be effective in
preventing HBV transmission (141–144), but with the avail-
ability of hepatitis B vaccine, HBIG typically is used as an
adjunct to vaccination.
The major determinant of the effectiveness of PEP is early
administration of the initial dose of vaccine. The effectiveness
of PEP diminishes the longer it is initiated after exposure
(17,145,146). Studies are limited on the maximum interval
after exposure during which PEP is effective, but the interval
is unlikely to exceed 7 days for perinatal (147) and needlestick
(140–142) exposures and 14 days for sexual exposures (122,
138,139,143,144).
No data are available on the efficacy of HBsAg-containing
combination vaccines when used to complete the vaccine series
for PEP, but the efficacy of combination vaccines is expected to
be similar to that of single-antigen vaccines because the HBsAg
component induces a comparable anti-HBs response.
TABLE 5. Hepatitis B vaccine schedules for children, adolescents,
and adults*
Age Schedule
Children (1–10 yrs) 0, 1, and 6 mos†
0, 2, and 4 mos†
0, 1, 2, and 12 mos†§
Adolescents (11–19 yrs) 0, 1, and 6 mos†
0, 1, and 4 mos†
0, 2, and 4 mos†
0, 12, and 24 mos†
0 and 4–6 mos¶**
0, 1, 2, and 12 mos†¶
Adults (>20 yrs) 0, 1, and 6 mos**††
0, 1, and 4 mos**
0, 2, and 4 mos**
0, 1, 2, and 12 mos¶**
* Children, adolescents, and adults may be vaccinated according to any of
the schedules indicated, except as noted. Selection of a schedule should
consider the need to optimize compliance with vaccination
† Pediatric/adolescent formulation.
¶ A 2-dose schedule of Recombivax-HB adult formulation (10 µg) is
licensed for adolescents aged 11–15 years. When scheduled to receive
the second dose, adolescents aged >15 years should be switched to a
3-dose series, with doses 2 and 3 consisting of the pediatric formulation
administered on an appropriate schedule.
§ A 4-dose schedule of Engerix B is licensed for all age groups.
** Adult formulation.
†† Twinrix may be administered to persons aged >18 years at 0, 1, and 6
months.
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Perinatal HBV Exposure
Passive-active PEP. PEP with hepatitis B vaccine and HBIG
administered 12–24 hours after birth, followed by comple-
tion of a 3-dose vaccine series, has been demonstrated to be
85%–95% effective in preventing acute and chronic HBV
infection in infants born to women who are positive for both
HBsAg and HBeAg (137). Although clinical trials have evalu-
ated the efficacy of passive-active PEP with hepatitis B vac-
cine and HBIG administered only within 24 hours of birth,
studies of passive immunoprophylaxis have demonstrated that
HBIG provided protection when administered as late as 72
hours after exposure. The majority of clinical trials have evalu-
ated the efficacy of passive-active PEP when the second vac-
cine dose was administered at age 1 month (137).
Administration of HBIG plus vaccine at birth, 1 month, and
6 months and at birth, 2 months, and 6 months has demon-
strated comparable efficacy in prevention of acute and chronic
infection among infants born to women who were both HBsAg
and HBeAg positive (Cladd E. Stevens, MD, New York Blood
Center, personal communication, 1994).
Infants born to HBsAg-positive/HBeAg-negative mothers
who receive passive-active PEP with HBIG and hepatitis B
vaccine should have the same high degree of protection as
infants born to women who are HBsAg positive/HBeAg posi-
tive. However, the efficacy of this regimen has not been exam-
ined in controlled clinical trials because the low infection rate
would require an unattainable sample size.
Active PEP. Active PEP with hepatitis B vaccine alone (i.e.,
without HBIG) is frequently used in certain remote areas (e.g.,
Alaska and the Pacific Islands) where implementation of
maternal HBsAg testing is difficult because no access exists to
a laboratory. In randomized, placebo-controlled clinical tri-
als, administration of hepatitis B vaccine in a 3- or 4-dose
schedule without HBIG beginning <12 hours after birth has
been demonstrated to prevent 70%–95% of perinatal HBV
infections among infants born to women who are positive for
both HBsAg and HBeAg (58,148–152). Population-based
studies in areas with a high endemicity of HBV infection have
demonstrated that active postexposure vaccination is highly
effective in preventing infection when the first dose is admin-
istered soon after birth, the second at age 1–2 months, and
the third at age 6–8 months (153–155).
Vaccine Safety
Hepatitis B vaccines have been demonstrated to be safe when
administered to infants, children, adolescents, and adults. Since
1982, an estimated >60 million adolescents and adults and
>40 million infants and children have been vaccinated in the
United States.
Vaccine Reactogenicity
The most frequently reported side effects among persons
receiving hepatitis B vaccine are pain at the injection site
(3%–29%) and fever >99.9° F (>37.7° C) (1%–6%)
(156,157). However, in placebo-controlled studies, these side
effects were reported no more frequently among persons
receiving hepatitis B vaccine than among persons receiving
placebo (87). Administration of hepatitis B vaccine soon after
birth has not been associated with an increased rate of elevated
temperatures or microbiologic evaluations for possible sepsis
in the first 21 days of life (158).
Adverse Events
A causal association has been established between receipt of
hepatitis B vaccine and anaphylaxis (159). On the basis of
data from the Vaccine Safety Datalink (VSD) project, the
estimated incidence of anaphylaxis among children and ado-
lescents who received hepatitis B vaccine is one case per 1.1
million vaccine doses distributed (95% confidence interval =
0.1–3.9) (160).
Early postlicensure surveillance of adverse events suggested
a possible association between Guillain-Barré syndrome and
receipt of the first dose of plasma-derived hepatitis B vaccine
among U.S. adults (161). However, in a subsequent analysis
of Guillain-Barré syndrome cases reported to CDC, FDA, and
vaccine manufacturers, among an estimated 2.5 million adults
who received >1 dose of recombinant hepatitis B vaccine dur-
ing 1986–1990, the rate of Guillain-Barré syndrome
occurring after hepatitis B vaccination did not exceed the back-
ground rate among unvaccinated persons (CDC, unpublished
data, 1992). A review by persons with clinical expertise con-
cluded that evidence was insufficient to reject or accept a causal
association between Guillain-Barré syndrome and hepatitis B
vaccination (159,162).
Multiple sclerosis (MS) has not been reported after hepati-
tis B vaccination among children. However, one retrospective
case-control study (163,164) reported an association between
hepatitis B vaccine and MS among adults. Multiple other stud-
ies (165–168) have demonstrated no association between hepa-
titis B vaccine and MS. Reviews of these data by panels of
persons with clinical expertise have favored rejection of a causal
association between hepatitis B vaccination and MS (169,170).
Chronic illnesses that have been reported in rare instances
after hepatitis B vaccination include chronic fatigue syndrome
(171), neurologic disorders (e.g., leukoencephalitis, optic neu-
12 MMWR December 23, 2005
ritis, and transverse myelitis) (172–174), rheumatoid arthri-
tis (175,176), type 1 diabetes (177), and autoimmune disease
(178). No evidence of a causal association between these con-
ditions or other chronic illnesses and hepatitis B vaccine has
been demonstrated (159,169,170,179–182).
Reported episodes of alopecia (hair loss) after rechallenge
with hepatitis B vaccine suggest that vaccination might, in
rare cases, trigger episodes of alopecia (183). However, a popu-
lation-based study determined no statistically significant
association between alopecia and hepatitis B vaccine (184).
No evidence exists of a causal association between hepatitis
B vaccination, including administration of the birth dose, and
sudden infant death syndrome (SIDS) or other causes of death
during the first year of life (185–187). Infant death rates,
including rates of SIDS, declined substantially in the United
States during the 1990s, coincident with an increase in infant
hepatitis B vaccination coverage from <1% to >90% and
implementation of efforts to reduce SIDS through infant sleep
positioning and separation from other persons in bed (188).
The safety of hepatitis B vaccine and other vaccines is
assessed continuously through ongoing monitoring of data from
VSD, the Vaccine Adverse Events Reporting System (VAERS),
and other surveillance systems. Any adverse events after vaccina-
tion should be reported to VAERS; report forms and assistance
are available from CDC at telephone 1-800-822-7967 or at
http://www.vaers.hhs.gov.
Contraindications and Precautions
Hepatitis B vaccination is contraindicated for persons with
a history of hypersensitivity to yeast or to any vaccine compo-
nent (92,189–191). Despite a theoretic risk for allergic reac-
tion to vaccination in persons with allergy to Saccharomyces
cerevisiae (baker’s yeast), no evidence exists that documents
adverse reactions after vaccination of persons with a history
of yeast allergy.
Persons with a history of serious adverse events (e.g., ana-
phylaxis) after receipt of hepatitis B vaccine should not
receive additional doses. As with other vaccines, vaccination
of persons with moderate or severe acute illness, with or with-
out fever, should be deferred until the illness resolves (192).
Vaccination is not contraindicated in persons with a history
of MS, Guillain-Barré syndrome, autoimmune disease (e.g.,
systemic lupus erythematosis or rheumatoid arthritis), or other
chronic diseases.
Pregnancy is not a contraindication to vaccination. Limited
data indicate no apparent risk for adverse events to develop-
ing fetuses when hepatitis B vaccine is administered to preg-
nant women (193). Current vaccines contain noninfectious
HBsAg and should cause no risk to the fetus.
Future Considerations
Implementation of the recommendations and strategies in
this document should ultimately lead to the elimination of
HBV transmission in the United States. New information will
have implications for this effort, and adjustments and changes
are expected to occur.
Long-Term Protection and Booster
Doses
Studies are needed to assess long-term protection after vacci-
nation and the possible need for booster doses of vaccine. The
longest follow-up studies of vaccine protection have been con-
ducted in populations with an initially high endemicity of HBV
infection (i.e., >8% prevalence of chronic infection) (130).
Implementation of hepatitis B vaccination programs in popu-
lations with a high endemicity of HBV infection has resulted in
virtual elimination of new HBV infections by providing vac-
cine-induced immunity to susceptible persons. In these popu-
lations, ongoing exposure of vaccinated persons to persons with
chronic HBV infection might complicate future efforts to as-
sess long-term hepatitis B vaccine efficacy. Assessment of effi-
cacy provided by hepatitis B immunization after 15–20 years
will require studies among populations that continue to have
exposures to HBsAg-positive persons (e.g., communities of im-
migrants from highly endemic countries, populations of
injection-drug users, or health-care workers) and studies among
populations with a low prevalence of infection.
Immunization Escape Mutants
Mutations in the S gene of HBV can lead to conforma-
tional changes in the a determinant of the HBsAg protein,
which is the major target for neutralizing anti-HBs. These
variants have been detected in humans infected with HBV,
and concern has been expressed that these variants might rep-
licate in the presence of vaccine-induced anti-HBs or anti-
HBs contained in HBIG (194,195). Although no evidence
suggests that S gene immunization escape mutants pose a threat
to existing programs using hepatitis B vaccines (196), further
studies and enhanced surveillance to detect the emergence of
these variants are high priorities for monitoring the effective-
ness of current vaccination strategies.
Recommendations for Hepatitis B
Vaccination of Infants, Children,
and Adolescents
This section outlines updated ACIP recommendations and
associated implementation strategies for hepatitis B vaccina-
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tion of infants, children, and adolescents. These recommen-
dations have been summarized (Box 3).
Prevention of Perinatal HBV Infection
and Management of Pregnant Women
Recommendations
Prenatal HBsAg Testing
• All pregnant women should be tested routinely for HBsAg
during an early prenatal visit (e.g., first trimester) in each preg-
nancy, even if they have been previously vaccinated or tested.
• Women who were not screened prenatally, those who
engage in behaviors that put them at high risk for infec-
tion (e.g., injection-drug use, having had more than one
sex partner in the previous 6 months or an HBsAg-posi-
tive sex partner, evaluation or treatment for a sexually
transmitted disease [STD], or recent or current injection-
drug use) and those with clinical hepatitis should be tested
at the time of admission to the hospital for delivery.
• All laboratories that provide HBsAg testing of pregnant
women should use an FDA-licensed or -approved HBsAg
test and should perform testing according to the
manufacturer’s labeling, including testing of initially reac-
tive specimens with a licensed neutralizing confirmatory
test. When pregnant women are tested for HBsAg at the
time of admission for delivery, shortened testing protocols
may be used and initially reactive results reported to expe-
dite administration of immunoprophylaxis to infants.
• Women who are HBsAg positive should be referred to an
appropriate case-management program to ensure that their
infants receive timely postexposure prophylaxis and follow-
up (see Case-Management Programs to Prevent Perinatal
HBV Infection). In addition, a copy of the original labo-
ratory report indicating the pregnant woman’s HBsAg sta-
tus should be provided to the hospital where delivery is
planned and to the health-care provider who will care for
the newborn.
• Women who are HBsAg positive should be provided with
or referred for appropriate counseling and medical man-
agement (Appendix A). HBsAg-positive pregnant women
should receive information concerning hepatitis B that
discusses
— modes of transmission;
— perinatal concerns (e.g., infants born to HBsAg-
positive mothers may be breast fed);
— prevention of HBV transmission to contacts, includ-
ing the importance of postexposure prophylaxis for
the newborn infant and hepatitis B vaccination for
household, sexual, and needle-sharing contacts;
— substance abuse treatment, if appropriate; and
— medical evaluation and possible treatment of chronic
hepatitis B.
• When HBsAg testing of pregnant women is not feasible
(i.e., in remote areas without access to a laboratory), all
infants should receive hepatitis B vaccine <12 hours of
birth and should complete the hepatitis B vaccine
series according to a recommended schedule for infants
born to HBsAg-positive mothers (Tables 2 and 3).
Management of Infants Born to Women Who Are
HBsAg Positive
• All infants born to HBsAg-positive women should receive
single-antigen hepatitis B vaccine (Table 2) and HBIG
BOX 3. Summary of hepatitis B vaccination recommendations
for infants, children, and adolescents
Maternal hepatitis B surface antigen (HBsAg) testing




• Infants born to mothers who are HBsAg positive should
receive hepatitis B vaccine and hepatitis B immune
globulin (HBIG) <12 hours of birth.
• Infants born to mothers whose HBsAg status is unknown
should receive hepatitis B vaccine <12 hours of birth.
The mother should have blood drawn as soon as pos-
sible to determine her HBsAg status; if she is HBsAg
positive, the infant should receive HBIG as soon as pos-
sible (no later than age 1 week).
• Full-term infants who are medically stable and weigh
>2,000 g born to HBsAg-negative mothers should re-
ceive single-antigen hepatitis B vaccine before hospital
discharge.
• Preterm infants weighing <2,000 g born to HBsAg-
negative mothers should receive the first dose of vaccine
1 month after birth or at hospital discharge.
After the birth dose
• All infants should complete the hepatitis B vaccine
series with either single-antigen vaccine or combination
vaccine, according to a recommended vaccination sched-
ule (see Tables 3 and 4).
• Infants born to HBsAg-positive mothers should be tested
for HBsAg and antibody to HBsAg after completion of
the hepatitis B vaccine series at age 9–18 months.
Vaccination of children and adolescents
• All unvaccinated children and adolescents aged <19 years
should receive the hepatitis B vaccine series.
14 MMWR December 23, 2005
(0.5 mL) <12 hours of birth, administered at different
injection sites. The vaccine series should be completed
according to a recommended schedule for infants born to
HBsAg-positive mothers (Table 3). The final dose in the
vaccine series should not be administered before age 24
weeks (164 days).
• For preterm infants weighing <2,000 g, the initial vac-
cine dose (birth dose) should not be counted as part of
the vaccine series because of the potentially reduced
immunogenicity of hepatitis B vaccine in these infants; 3
additional doses of vaccine (for a total of 4 doses) should
be administered beginning when the infant reaches age 1
month (Tables 3 and 4).
• Postvaccination testing for anti-HBs and HBsAg should
be performed after completion of the vaccine series, at
age 9–18 months (generally at the next well-child visit).
Testing should not be performed before age 9 months to
avoid detection of anti-HBs from HBIG administered
during infancy and to maximize the likelihood of detect-
ing late HBV infection. Anti-HBc testing of infants is
not recommended because passively acquired maternal
anti-HBc might be detected in infants born to HBV-
infected mothers to age 24 months.
— HBsAg-negative infants with anti-HBs levels >10 mIU/mL
are protected and need no further medical manage-
ment.
— HBsAg-negative infants with anti-HBs levels <10 mIU/mL
should be revaccinated with a second 3-dose series and
retested 1–2 months after the final dose of vaccine.
— Infants who are HBsAg positive should receive appro-
priate follow-up (Appendix A).
• Infants of HBsAg-positive mothers may be breast fed
beginning immediately after birth.
• Although not indicated in the manufacturer’s package
labeling, HBsAg-containing combination vaccines may
be used for infants aged >6 weeks born to HBsAg-
positive mothers to complete the vaccine series after
receipt of a birth dose of single-antigen hepatitis B vac-
cine and HBIG.
Management of Infants Born to Women with Unknown
HBsAg Status
• Women admitted for delivery without documentation of
HBsAg test results should have blood drawn and tested as
soon as possible after admission.
• While test results are pending, all infants born to women
without documentation of HBsAg test results should
receive the first dose of single-antigen hepatitis B vaccine
(without HBIG) <12 hours of birth (Tables 2 and 3).
— If the mother is determined to be HBsAg positive, her
infant should receive HBIG as soon as possible but no
later than age 7 days, and the vaccine series should be
completed according to a recommended schedule for
infants born to HBsAg-positive mothers (Table 3).
— If the mother is determined to be HBsAg negative, the
vaccine series should be completed according to a
recommended schedule for infants born to HBsAg-
negative mothers (Table 3).
— If the mother has never been tested to determine her
HBsAg status, the vaccine series should be completed
according to a recommended schedule for infants born
to HBsAg-positive mothers (Table 3). Administration
of HBIG is not necessary for these infants.
• Because of the potentially decreased immunogenicity of
vaccine in preterm infants weighing <2,000 g, these
infants should receive both single-antigen hepatitis B vac-
cine and HBIG (0.5 mL) if the mother’s HBsAg status
cannot be determined <12 hours of birth. The birth dose
of vaccine should not be counted as part of the 3 doses
required to complete the vaccine series; 3 additional doses
of vaccine (for a total of 4 doses) should be administered
according to a recommended schedule on the basis of the
mother’s HBsAg test result (Table 3).
Vaccination of Pregnant Women
• Pregnant women who are identified as being at risk for
HBV infection during pregnancy (e.g., having more than
one sex partner during the previous 6 months, been evalu-
ated or treated for an STD, recent or current injection-
drug use, or having had an HBsAg-positive sex partner)
should be vaccinated.
• Pregnant women at risk for HBV infection during preg-
nancy should be counseled concerning other methods to
prevent HBV infection.
Implementation
Delivery Hospital Policies and Procedures
• All delivery hospitals should implement policies and pro-
cedures (Box 4) to ensure 1) identification of infants born
to HBsAg-positive mothers and infants born to mothers
with unknown HBsAg status (see Prenatal HBsAg Test-
ing), and 2) initiation of immunization for these infants).
Such policies and procedures should include the follow-
ing standing orders:
— for all pregnant women, review of HBsAg test results
at the time of admission for delivery;
— for women who do not have a documented HBsAg
test result, HBsAg testing as soon as possible after
admission for delivery;
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— identification and management of all infants born to
HBsAg-positive mothers;
— identification and management of all infants born to
mothers with unknown HBsAg status; and
— for all infants, documentation on the infant’s medical
record of maternal HBsAg test results, infant hepatitis
B vaccine administration, and administration of HBIG
(if appropriate).
• Delivery hospitals should enroll in the federally funded
Vaccines for Children (VFC) program to obtain free hepa-
titis B vaccine for administration of the birth dose to new-
borns who are eligible (i.e., Medicaid eligible, American
Indian or Alaska Native, underinsured, or uninsured).
Case-Management Programs to Prevent Perinatal HBV
Infection
• States and localities should establish case-management
programs (Box 5), including appropriate policies, proce-
dures, laws, and regulations, to ensure that
— all pregnant women are tested for HBsAg during each
pregnancy, and
— infants born to HBsAg-positive women and infants
born to women with unknown HBsAg status receive
recommended case management.
• The location of these programs and the methods by which
they operate will depend on multiple factors (e.g., popu-
lation density and annual caseload of HBsAg-positive
women). Programs may be located in state or local health
departments, private health-care systems (e.g., health
maintenance organizations), or institutions (e.g., correc-
tional facility systems). Program administrators will need
to work with prenatal care providers, delivery hospital staff,
pediatric care providers, private health-care systems, and
health departments.
Universal Vaccination of Infants
Recommendations
• All infants should receive the hepatitis B vaccine series as
part of the recommended childhood immunization sched-
ule (Table 5 and Appendix B). (For recommendations on
management of infants born to HBsAg-positive mothers
and infants born to mothers with unknown HBsAg sta-
tus, see Prevention of Perinatal HBV Infection and Man-
agement of Pregnant Women.)
• For all medically stable infants weighing >2,000 g at birth
and born to HBsAg-negative mothers, the first dose of
vaccine should be administered before hospital discharge.
Only single-antigen hepatitis B vaccine should be used
for the birth dose.
BOX 4. Delivery hospital policies and procedures to prevent
perinatal HBV transmission
At time of admission for delivery
• Review hepatitis B surface antigen (HBsAg) status of all
pregnant women.
• Record maternal HBsAg test results on both labor and
delivery record and on infant’s delivery summary sheet.
• Perform HBsAg testing as soon as possible on women who
— do not have a documented HBsAg test result,
— were at risk for HBV infection during pregnancy
(e.g., more than one sex partner in the previous 6
months, evaluation or treatment for a sexually trans-
mitted disease, recent or current injection-drug use,
or HBsAg-positive sex partner), or
— had clinical hepatitis since previous testing.
After delivery
HBsAg-positive mothers and their infants
• Administer single-antigen hepatitis B vaccine and hepa-
titis B immune globulin (HBIG) to all infants born to
HBsAg-positive mothers <12 hours after birth and
record date and time of administration of HBIG and
hepatitis B vaccine in infant’s medical record.
• Provide information regarding hepatitis B to HBsAg-
positive mothers, including
— advice that they may breast feed their infants upon
delivery;
— modes of HBV transmission;
— need for vaccination of their susceptible household,
sexual, and needle-sharing contacts;
— need for substance abuse treatment, if appropriate; and
— need for medical management and possible treat-
ment for chronic hepatitis B.
Mothers with unknown HBsAg status and their infants
• Administer single-antigen hepatitis B vaccine (without
HBIG) to all infants born to mothers with unknown HBsAg
status <12 hours after birth and record date and time of
administration of hepatitis B vaccine on infant’s medical record.
• Alert infant’s pediatric health-care provider if an infant
is discharged before the mother’s HBsAg test result is
available; if the mother is determined to be HBsAg posi-
tive, HBIG should be administered to the infant as soon
as possible, but no later than age 7 days.
All mothers and their infants
• Administer a dose of single-antigen hepatitis B vaccine
to all infants weighing >2,000 g.
• Ensure that all mothers have been tested for HBsAg
prenatally or at the time of admission for delivery and
document test results.
At time infant is discharged
• Provide infant’s immunization record to mother and
remind her to take it to the infant’s first visit to pediat-
ric health-care provider.
16 MMWR December 23, 2005
BOX 5. Components of case-management programs to prevent perinatal hepatitis B virus infection
Identify and manage infants born to mothers without
HBsAg test results
• Delivery hospitals should implement policies and pro-
cedures to ensure identification and initiation of
postexposure immunization of infants born to mothers
with unknown HBsAg status at delivery (see Delivery
Hospital Policies and Procedures).
• Delivery hospitals should document the date and time
of birth, date and time of administration of hepatitis B
vaccine, and maternal HBsAg test results for all infants
born to mothers with unknown HBsAg status at the
time of delivery.
Complete the hepatitis B vaccine series
• Practitioners should document the dates of administra-
tion of all doses of the hepatitis B vaccine series for all
infants born to HBsAg-positive mothers.
Complete postvaccination testing
• Health-care providers should document the results of test-
ing for HBsAg and antibody to hepatitis B surface antigen
(anti-HBs) after completion of the hepatitis B vaccine
series for all infants born to HBsAg-positive mothers.
Monitor and evaluate the case management program
• Annually, each program should track
— the number of HBsAg-positive pregnant women;
— the proportion of infants born to HBsAg-positive
women receiving postexposure prophylaxis <12
hours of birth, third vaccine dose by age 6 months,
and postvaccination serologic testing for HBsAg and
anti-HBs;
— the number of delivering women with unknown
HBsAg status; and
— the proportion of infants born to mothers with
unknown HBsAg status receiving hepatitis B vac-
cine within 12 hours of birth.
• Programs should determine reasons for
— >10% difference between expected and identified
number of HBsAg-positive pregnant women;
— <90% completion rates for HBIG and hepatitis B
vaccine <12 hours of birth, third dose by age 6
months, and postvaccination testing for infants born
to HBsAg-positive mothers; and
— <90% completion rates for hepatitis B vaccine <12
hours of birth for infants born to mothers with
unknown HBsAg status.
Test all pregnant women for hepatitis B surface antigen
(HBsAg)
• Health-care providers should test all pregnant women
for HBsAg during each pregnancy.
• HBsAg testing should be incorporated into standard
prenatal testing panels (e.g., blood type, human immuno-
deficiency virus) infection, Rh factor, rubella antibody
titer, and syphilis infection) used by all health-care
providers caring for pregnant women.
• Delivery hospitals should ensure that all pregnant or
delivering women have been tested for HBsAg before
hospital discharge.
• Reporting of HBsAg test status should be included on
hospital-based electronic birth certificates or neonatal
metabolic screening requests.
Report and track HBsAg-positive women
• All HBsAg-positive pregnant women and all women of
childbearing age with HBsAg-positive laboratory results
should be reported to state or local perinatal hepatitis B
prevention programs.
• All HBsAg-positive pregnant women should be entered
into case-management tracking systems.
Provide prenatal HBsAg testing records to delivery
hospitals
• HBsAg test results should be included on all forms (hard
copy, electronic) used by practitioners to record and
transmit information regarding care during pregnancy.
• For all pregnant women, a copy of the original labora-
tory report of HBsAg test results should be transferred
from the prenatal care provider to the delivery hospital.
• Practitioners should document that HBsAg-positive
pregnant women have a copy of the original laboratory
report, that a copy of the original laboartory report is
transferred from the prenatal care provider to the deliv-
ery hospital, and that patients are informed of their
HBsAg test status and advised to notify delivery staff.
Identify and manage infants born to HBsAg-positive
mothers
• Delivery hospitals should implement policies and pro-
cedures to ensure identification and initiation of
postexposure immunization of infants born to HBsAg-
positive mothers (see Delivery Hospital Policies and Pro-
cedures).
• Delivery hospitals should document the date and time
of birth and the date and time of administration of hepa-
titis B immune globulin (HBIG) and hepatitis B vac-
cine for all infants born to HBsAg-positive mothers.
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• On a case-by-case basis and only in rare circumstances,
the first dose may be delayed until after hospital discharge
for an infant who weighs >2,000 g and whose mother is
HBsAg negative.
— When such a decision is made, a physician’s order to
withhold the birth dose and a copy of the original labo-
ratory report indicating that the mother was HBsAg
negative during this pregnancy should be placed in
the infant’s medical record.
— For infants who do not receive a first dose before hos-
pital discharge, the first dose should be administered
no later than age 2 months.
— Situations in which the birth dose should not be
delayed include any high-risk sexual or drug-using
practices of the infant’s mother during pregnancy (e.g.,
having had more than one sex partner during the pre-
vious 6 months or an HBsAg-positive sex partner,
evaluation or treatment for an STD, or recent or cur-
rent injection-drug use) and expected poor compli-
ance with follow-up to initiate the vaccine series.
• Preterm infants weighing <2,000 g and born to HBsAg-
negative mothers should have their first vaccine dose
delayed until 1 month after birth or hospital discharge
(Table 4). For these infants, a copy of the original labora-
tory report indicating that the mother was HBsAg nega-
tive during this pregnancy should be placed in the infant’s
medical record.
• The vaccine series should be completed according to a
recommended schedule with either single-antigen vaccine
or a combination vaccine that contains the hepatitis B
vaccine antigen (e.g., Hib-hepatitis B or DTaP-IPV-
hepatitis B) (Table 2). The final dose in the vaccine series
should not be administered before age 24 weeks (164 days).
• Administration of 4 doses of hepatitis B vaccine to
infants is permissible in certain situations (e.g., when com-
bination vaccines are administered after the birth dose).
• In populations with currently or previously high rates of
childhood HBV infection (i.e., Alaska Natives; Pacific
Islanders; and immigrant families from Asia, Africa, and
other regions with intermediate or high endemic rates of
infection [Figure 1 and Box 2]), the first dose of hepatitis
B vaccine should be administered at birth and the final
dose at age 6–12 months.
Implementation
• All delivery hospitals should implement standing orders
for administration of hepatitis B vaccination as part of
routine medical care of all medically stable infants weigh-
ing >2,000 g at birth (Box 4).
• All delivery hospitals should implement policies and pro-
cedures for management of infants weighing <2,000 g at
birth, including the following:
— ensuring initiation of postexposure immunization of
infants born to HBsAg-positive mothers and infants
born to mothers not screened for HBsAg prenatally
(see Prevention of Perinatal HBV Infection and Man-
agement of Pregnant Women), and
— documentation of maternal HBsAg test results on the
infant’s medical record.
• Prenatal care education should include information
regarding the rationale for and importance of newborn
hepatitis B vaccination.
• States are encouraged to adopt regulations or laws that
require hepatitis B vaccination for entry into child care
and also for entry into kindergarten and/or elementary
school to ensure high vaccine coverage among infants and
children.
Vaccination of Children and Adolescents
Who Were Not Previously Vaccinated
Recommendations
• Hepatitis B vaccination is recommended for all children
and adolescents aged <19 years.
• Children and adolescents who have not previously received
hepatitis B vaccine should be vaccinated routinely at any
age with an appropriate dose and schedule (Tables 2 and
5). Selection of a vaccine schedule should consider the
need to achieve completion of the vaccine series. In all
settings, vaccination should be initiated even though
completion of the vaccine series might not be ensured.
Implementation
• To ensure high vaccination coverage among children and
adolescents, the following measures are recommended:
— All children aged 11–12 years should have a review of
their immunization records and should complete the
vaccine series if they were not previously vaccinated or
were incompletely vaccinated.
— All children and adolescents aged <19 years (includ-
ing internationally adopted children) who were born
in Asia, the Pacific Islands, Africa, or other intermedi-
ate- or high-endemic countries (Figure 1 and Box 2)
or who have at least one parent who was born in one
of these areas should have a review of their immuniza-
tion records and should complete the vaccine series if
they were not previously vaccinated or were incom-
pletely vaccinated.
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— States are encouraged to adopt regulations or laws that
require hepatitis B vaccination before entry into middle
school or its equivalent.
— Vaccination requirements should be considered for
older high school students and for students before col-
lege entry, when feasible.
— States are encouraged to expand or implement immu-
nization registries to include adolescents.
— Hepatitis B vaccine should be offered to all unvacci-
nated adolescents in settings that provide health-care
services to this age group (Box 6), particularly those
who engage in behaviors that place them at high risk
for HBV infection.
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Appendix A
Case Finding and Management of Hepatitis B Surface Antigen (HBsAg)–
Positive Persons During Delivery of Vaccination Services
— Providers should identify children born in high-
endemic countries and provide HBsAg testing and fol-
low-up in all settings that provide health care. Retesting
of persons who were tested for HBsAg in other coun-
tries should be considered.
• Other persons who should be tested for HBsAg as part of
vaccination services include
— all pregnant women (See Prevention of Perinatal HBV
Infection and Management of Pregnant Women),
— persons who receive prevaccination testing for suscep-
tibility and who test positive for anti-HBc (See Pre-
vaccination Testing for Susceptibility),
— hemodialysis patients, and
— nonresponders to vaccination (See Appendix B, Post-
vaccination Testing for Serologic Response).
Management of Persons Identified
as HBsAg Positive
• All persons with HBsAg-positive laboratory results should
be reported to the state or local health department.
• To verify the presence of chronic HBV infection, HBsAg-
positive persons should be retested. The absence of immu-
Chronically infected persons are at high risk for chronic
liver disease and are a major reservoir of hepatitis B virus (HBV)
infection. Foreign-born persons, especially persons from Af-
rica, Asia, and the Pacific Islands, have high* rates of chronic
HBV infection. During delivery of recommended hepatitis B
vaccination services (e.g., HBsAg screening of pregnant women
and serologic testing to assess susceptibility), vaccination pro-
viders will identify persons who are HBsAg positive. These
persons require counseling and medical management for
chronic HBV infection to reduce their risk for chronic liver
disease. Their susceptible household, sexual, and needle-shar-
ing contacts also need to be vaccinated against hepatitis B.
Few programs have been implemented to identify HBsAg-
positive persons, provide or refer these persons for appropri-
ate medical management, and provide vaccination to their
contacts (1). Extending these services to persons identified as
HBsAg positive will help prevent serious sequelae in chroni-
cally infected persons and enhance vaccination strategies for
elimination of HBV transmission. This Appendix addresses
case finding and management of persons with chronic HBV
infection in the context of vaccine delivery. The recommen-
dations are not intended to represent a comprehensive pre-
vention program for chronically infected persons.
Case Finding in the Context
of Vaccination Service Delivery
• All foreign-born persons (including immigrants, refugees,
asylum seekers, and internationally adopted children) born
in Asia, the Pacific Islands, Africa, and other regions with
high endemicity of HBV infection (Box A-1) should be
tested for HBsAg, regardless of vaccination status.
— For all persons born in high-endemic countries who
are applying for permanent U.S. residence, HBsAg
screening and appropriate follow-up on the basis of
HBsAg test results should be included as part of the
required overseas premigration and domestic adjust-
ment-of-visa status medical examination process (2).
HBsAg-positive persons should be considered eligible
for migration and adjustment-of-visa status and coun-
seled and recommended for follow-up medical evalu-
ation and management in U.S. resettlement
communities.
BOX A-1. Geographic areas with high* hepatitis B virus
endemicity
Africa: all countries except Algeria, Egypt, Lybia, and
Tunisia
South Asia: all countries except Afghanistan, Bangladesh,
Bhutan, India, Malaysia, Maldives, Nepal, Pakistan,
and Sri Lanka
Western Pacific: all countries except Australia, Guam,
Japan, and New Zealand
Middle East: Jordan and Saudi Arabia
Eastern Europe and Newly Independent States of the
former Soviet Union: Albania, Armenia, Azerbaijan,
Bulgaria, Croatia, Georgia, Kazakhstan, Kyrgyzstan,
Moldova, Tajikistan, Turkmenistan, and Uzbekistan
Western Europe: Malta
North America: Alaska Natives and indigenous popula-
tions in Northern Canada and Greenland
South America: Amazonian areas of Bolivia, Brazil,
Columbia, Peru, and Venezuela
* Hepatitis B surface antigen prevalence of >8%.
* Hepatitis B surface antigen prevalence of >8%.
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noglobulin M antibody to HBcAg or the persistence of
HBsAg for 6 months indicates chronic HBV infection.
• Persons with chronic HBV infection should be referred
for evaluation by a physician experienced in the manage-
ment of chronic liver disease (3). Certain patients with
chronic hepatitis B will benefit from early intervention
with antiviral treatment or screening to detect hepatocel-
lular carcinoma at an early stage.
• Household, sexual, and needle-sharing contacts of chroni-
cally infected persons should be identified. Unvaccinated
sex partners and household and needle-sharing contacts
should be tested for susceptibility to HBV infection (see
Prevaccination Serologic Testing for Susceptibility) and
should receive the first dose of hepatitis B vaccine imme-
diately after collection of the blood sample for serologic
testing. Susceptible persons should complete the vaccine
series using an age-appropriate vaccine dose and schedule
(see Tables 2 and 6) Persons who are not fully vaccinated
should complete the vaccine series.
• Sex partners of HBsAg-positive persons should be coun-
seled to use methods (e.g., condoms) to protect them-
selves from sexual exposure to infectious body fluids (e.g.,
semen or vaginal secretions) unless they have been dem-
onstrated to be immune after vaccination (i.e., anti-HBs
>10 mIU/mL) or previously infected (anti-HBc positive).
• To prevent or reduce the risk for transmission to others,
HBsAg-positive persons should be advised concerning the
risks for
— perinatal transmission to infants born to HBsAg-
positive women and the need for such infants to
receive hepatitis B vaccine beginning at birth (see Pre-
vention of Perinatal HBV Infection and Management
of Pregnant Women) and
— transmission to household, sexual, and needle-sharing
contacts and the need for such contacts to receive hepa-
titis B vaccine.
• HBsAg-positive persons should also be advised to
— use methods (e.g., condoms) to protect nonimmune
sex partners from acquiring HBV infection from sexual
activity until the sex partners can be vaccinated and
immunity documented;
— cover cuts and skin lesions to prevent the spread of
infectious secretions or blood;
— refrain from donating blood, plasma, tissue, or semen
(organs may be donated to HBV-immune or chroni-
cally infected persons needing a transplant); and
— refrain from sharing household articles (e.g., tooth-
brushes, razors, or personal injection equipment) that
could become contaminated with blood.
• To protect the liver from further harm, HBsAg-positive
persons should be advised to
— avoid or limit alcohol consumption because of the
effects of alcohol on the liver;
— refrain from beginning to take any new medicines,
including over-the-counter and herbal medicines, with-
out consulting their health-care provider; and
— obtain vaccination against hepatitis A if chronic liver
disease is found to be present.
• When seeking medical or dental care, HBsAg-positive per-
sons should be advised to inform those responsible for
their care of their HBsAg status so they can be evaluated
and their care managed appropriately.
• Other counseling messages:
— HBV is not spread by breastfeeding, kissing, hugging,
coughing, ingesting food or water, sharing eating uten-
sils or drinking glasses, or casual contact.
— Persons should not be excluded from school, play, child
care, work, or other settings on the basis of their HBsAg
status unless they are prone to biting (4).
— Involvement with a support group might help patients
cope with chronic HBV infection.
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Appendix B
Immunization Management Issues
response has been achieved (see Postvaccination Testing
for Serologic Response).
• Hepatitis B vaccine and other vaccines administered dur-
ing the same visit should be administered in different
injection sites. When more than one injection must be
administered in the same limb, the anterolateral thigh is
usually the preferred site, with injections separated by
1”–2” to avoid overlap in local reactions.
• For persons at risk for hemorrhage (e.g., persons with
hemophilia), the risk of bleeding after intramuscular
injection can be minimized by use of a 23-gauge (or
smaller) needle, application of direct pressure to the
injection site for >2 minutes, and administration of vac-
cine immediately after infusion of coagulation factor. Sub-
cutaneous administration of vaccine can be considered
for these persons but might result in lower response and
an increased local reaction.
• Hepatitis B vaccine should be stored at 35°–46° F (2°–8° C)
and should not be frozen.
• A vaccine information statement (VIS) must be provided
to recipients of hepatitis B vaccine. The National Child-
hood Vaccine Injury Act of 1986 (42 U.S.C. § 300aa-26)
requires vaccine providers to give a copy of the most cur-
rent vaccine-specific VIS to all recipients (children or their
guardians) of vaccines that are included on the National
Vaccine Injury Compensation Program table maintained
by the Health Resources and Services Administration
(available at http://www. hrsa.gov). Hepatitis B vaccine is
included on this table. The most current VIS for
hepatitis B vaccine is available at http://www.cdc.gov/nip/
publications/vis. Statements in languages other than
English are available from the Immunization Action
Coalition at http://www.immunize.org.
Hepatitis B Immune Globulin (HBIG)
Dose and Administration
• The standard dose of HBIG is 0.5 mL for postexposure
prophylaxis of infants born to hepatitis B surface antigen
(HBsAg)–positive women and 0.06 mL/kg for all other
applications.
• HBIG may be administered simultaneously with hepati-
tis B vaccine but in a different injection site.
• HBIG is administered by intramuscular injection. For
infants, HBIG should be administered intramuscularly
Hepatitis B Vaccine Dose
and Administration
• Recommended vaccine doses vary by product, age of
recipient, and needs of special populations (see Table 2).
Administration of single-antigen or combination vaccine
simultaneously with other childhood vaccines produces
no clinically significant interference in antibody responses
(1–13). Although the antigen contents of vaccines differ,
vaccines made by different manufacturers are interchange-
able, except for the 2-dose schedule used for adolescents
aged 11–15 years, for which only Recombivax HB is
approved. Combination vaccines are not approved for use
as a birth dose because of potential suppression of the
immune response to subsequent doses of the Haemophilus
influenzae type b (Hib) component in Comvax (14) and
possible decreased immunogenicity of the diphtheria com-
ponent of Pediarix when administered at birth.
• Hepatitis B vaccine should be administered by intramus-
cular injection. Injection into the buttock is associated
with decreased immunogenicity (15–18). Intradermal
administration can result in a lower seroconversion rate
and final concentration of antibody to hepatitis B surface
antigen compared with intramuscular administration; lim-
ited data are available to assess long-term protection from
this route of administration (19,20).
• The anterolateral thigh muscle is the recommended site
of administration for neonates (aged <1 month) and
infants (aged 1–12 months). For toddlers (aged 1–2 years)
and older children, either the anterolateral thigh or the
deltoid muscle may be used if the muscle mass is adequate.
The deltoid muscle is the preferred site of administration
for adolescents.
• For intramuscular injection, the needle should be long
enough to reach the muscle mass and prevent vaccine from
seeping into subcutaneous tissue, but not so long as to
involve underlying nerves and blood vessels or bone (21).
The appropriate needle length is usually 5/8” for neonates,
7/8”–1” for infants, and 7/8”–11/4” for toddlers, older chil-
dren, and adolescents. A 22- to 25-gauge needle should
be used.
• Hepatitis B vaccine administered by any route or site other
than intramuscularly in the anterolateral thigh or deltoid
muscle should not be counted as valid and should be
repeated unless serologic testing indicates that an adequate
28 MMWR December 23, 2005
in the anterolateral thigh using a 22–25-gauge needle that
is 7/8”–1” in length. For older children and adolescents,
an appropriate muscle mass (i.e., deltoid or gluteal) should
be chosen in which to deliver the larger volumes of HBIG
required for these age groups by using a needle length
appropriate for the person’s age and size (21).
• Vaccination with certain live-virus vaccines (measles,
mumps, rubella, and varicella) should be deferred for at
least 3 months after administration of HBIG because
HBIG can inhibit the response to these vaccines (21).
• HBIG should be stored at 35°–46° F (2°–8° C) and should
not be frozen.
Unknown or Uncertain Vaccination
Status
• A reliable vaccination history is defined as a written, dated
record (personal, school, physician, or immunization reg-
istry) of each dose of a complete series.
• In the majority of clinical practice settings and in situa-
tions when postexposure prophylaxis is indicated (see
Appendix C), providers should accept only written and
dated records (e.g., personal, school, physician, or im-
munization registry) as evidence of vaccination. Although
vaccinations should not be postponed if records cannot
be located, providers should try to locate missing records
by contacting previous health-care providers and search-
ing for personally held records.
• Persons whose records cannot be located should be con-
sidered susceptible and started or continued on the age-
appropriate vaccine schedule.
• Persons who reside in the United States but were vacci-
nated in other countries should be considered fully vacci-
nated if they have written documentation of >3 doses of
vaccine administered at recommended minimum inter-
vals, including the third dose at age >24 weeks. If they
were not vaccinated according to recommended minimum
intervals, they should be revaccinated (see Minimum
Dosing Intervals and Management of Persons Who Were
Incorrectly Vaccinated). Persons without written docu-
mentation of full vaccination should complete the age-
appropriate vaccine series.
Interrupted Vaccine Schedules
• When the hepatitis B vaccine schedule is interrupted, the
vaccine series does not need to be restarted.
• If the series is interrupted after the first dose, the second
dose should be given as soon as possible, and the second
and third doses should be separated by an interval of at
least 8 weeks.
• If only the third dose is delayed, it should be adminis-
tered as soon as possible, after age 24 weeks (164 days).
• It is not necessary to restart the vaccine series for infants
switched from one vaccine brand to another, including
combination vaccines.
Minimum Dosing Intervals
and Management of Persons
Who Were Incorrectly Vaccinated
• The third dose of vaccine must be administered at least 8
weeks after the second dose and should follow the first
dose by at least 16 weeks; the minimum interval between
the first and second doses is 4 weeks. In infants, adminis-
tration of the final dose is not recommended before age
24 weeks (164 days).
• Inadequate doses of hepatitis B vaccine (see Table 2) or
doses received after a shorter-than-recommended dosing
interval should be readministered.
Accelerated Vaccine Schedules
• The Food and Drug Administration (FDA) has not ap-
proved accelerated schedules in which hepatitis B vaccine
is administered more than once in a month. If clinicians
choose to use an accelerated schedule (i.e., doses at days
0, 7, and 14 days), the patient should also receive a booster
dose at least 6 months after the start of the series to pro-
mote long-term immunity.
Hemodialysis Patients and Other
Immunocompromised Persons
• Standard hepatitis B vaccine doses (see Table 2) are ap-
proved by FDA for vaccination of all persons aged <20
years. For hemodialysis patients and other immuno-
compromised persons, higher doses might be more
immunogenic, but no specific recommendations have
been made.
• Serologic testing of hemodialysis patients and other
immunocompromised persons is recommended 1–2
months after administration of the final dose of the pri-
mary vaccine series to determine the need for revaccina-
tion (see Postvaccination Testing for Serologic Response).
In addition, booster doses of vaccine might be needed
(see Booster Doses).
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Prevaccination Serologic Testing
for Susceptibility
• Because of the low prevalence of HBV infection among
infants, children, and adolescents born in the United
States, prevaccination testing for susceptibility usually is
not indicated for these age groups.
• Prevaccination testing for susceptibility is recommended
for unvaccinated household, sexual, and needle-sharing
contacts of HBsAg-positive persons.
• Anti-HBc is the test of choice for prevaccination testing.
• Persons tested for anti-HBc and found to be anti-HBc
negative are susceptible and should complete the vaccine
series.
• Persons found to be anti-HBc positive should be tested
for HBsAg. HBsAg testing may be performed on the same
specimen collected for anti-HBc testing. If the HBsAg
test result is positive, the person should receive appropri-
ate management (see Appendix A).
• In most situations, the first vaccine dose should be
administered immediately after collection of the blood
sample for serologic testing.
Postvaccination Testing for Serologic
Response
Recommendations for postvaccination testing of infants
born to HBsAg-positive women are provided in this report
(see Management of Infants Born to Women Who Are HBsAg
Positive). This section provides recommendations for post-
vaccination testing of other persons.
• Serologic testing for immunity is not necessary after rou-
tine vaccination of infants, children, or adolescents.
• Testing after vaccination is recommended only for the
following persons whose subsequent clinical management
depends on knowledge of their immune status:
— health-care workers;
— chronic hemodialysis patients, HIV-infected persons,
and other immunocompromised persons (e.g., hemato-
poietic stem-cell transplant recipients or persons
receiving chemotherapy), to determine the need for
revaccination and the type of follow-up testing; and
— sex partners of HBsAg-positive persons, to determine
the need for revaccination and the need for other meth-
ods of protection against HBV infection.
• Testing should be performed 1–2 months after adminis-
tration of the last dose of the vaccine series by using a
method that allows determination of a protective level of
anti-HBs (>10 mIU/mL).
• Persons found to have anti-HBs levels of >10 mIU/mL
after the primary vaccine series are considered to be im-
mune.
— Immunocompetent persons have long-term protection
and do not need further periodic testing to assess anti-
HBs levels.
— Immunosuppressed persons might need annual test-
ing to assess anti-HBs levels (see Booster Doses).
• Persons found to have anti-HBs levels of <10 mIU/mL
after the primary vaccine series should be revaccinated.
Administration of three doses on an appropriate schedule
(Table 7), followed by anti-HBs testing 1–2 months after
the third dose, is usually more practical than serologic
testing after one or more doses of vaccine.
• Persons who do not respond to revaccination should be
tested for HBsAg.
— If the HBsAg test result is positive, the persons should
receive appropriate management (see Appendix B), and
any household, sexual, or needle-sharing contacts
should be identified and vaccinated (see Appendix A).
— Persons who test negative for HBsAg should be con-
sidered susceptible to HBV infection and should be
counseled about precautions to prevent HBV infec-
tion and the need to obtain HBIG postexposure pro-
phylaxis for any known or likely parenteral exposure
to HBsAg-positive blood (see Appendix C).
Booster Doses
• Booster doses are not recommended for persons with
normal immune status who were vaccinated as infants,
children, or adolescents. Serologic testing is not recom-
mended to assess antibody levels in any age group, except
in specific circumstances (see Postvaccination Testing for
Serologic Response).
• For hemodialysis patients, the need for booster doses should
be assessed by annual antibody to hepatitis B survace anti-
gen (anti-HBs) testing. A booster dose should be adminis-
tered when anti-HBs levels decline to <10 mIU/mL.
• For other immunocompromised persons (e.g., HIV-
infected persons, hematopoietic stem cell transplant
recipients, and persons receiving chemotherapy), the need
for booster doses has not been determined. Annual anti-
HBs testing and booster doses when anti-HBs levels
decline to <10 mIU/mL should be considered in persons
with an ongoing high risk for exposure.
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Appendix C
Postexposure Prophylaxis of Persons with Discrete Identifiable
Exposures to Hepatitis B Virus (HBV)
This appendix provides recommendations for management
of persons who are exposed to HBV through a discrete, iden-
tifiable exposure to blood or body fluids that contain blood.
Recommendations for management of infants born to moth-
ers who test positive for hepatitis B surface antigen (HBsAg)-
positive mothers are provided in this report (see Prevention of
Perinatal HBV Transmission and Management of Pregnant
Women).
HBsAg-Positive Source
• Unvaccinated persons (Table C-1) or persons known not
to have responded to a complete hepatitis B vaccine series
should receive both hepatitis B immune globulin (HBIG)
and hepatitis B vaccine as soon as possible after exposure
(preferably <24 hours). For sexual exposures, HBIG
should not be administered more than 14 days after ex-
posure. Hepatitis B vaccine may be administered simul-
taneously with HBIG in a separate injection site. The
hepatitis B vaccine series should be completed using the
age-appropriate vaccine dose and schedule (see Tables 2
and 3).
• Persons who are in the process of being vaccinated but
who have not completed the vaccine series should receive
the appropriate dose of HBIG and should complete the
vaccine series.
• Children and adolescents who have written documenta-
tion of a complete hepatitis B vaccine series and who were
did not receive postvaccination testing should receive a
single vaccine booster dose.
Source with Unknown HBsAg Status
• Unvaccinated persons (Table C-1) should receive the hepa-
titis B vaccine series with the first dose initiated as soon as
possible after exposure, preferably <24 hours. The vac-
cine series should be completed using the age-appropri-
ate dose and schedule (see Tables 2, 3, and 5).
• Persons who are not fully vaccinated should complete the
vaccine series.
• Children and adolescents with written documentation of
a complete hepatitis B vaccine series require no further
treatment.
TABLE C-1. Guidelines for postexposure immunoprophylaxis of unvaccinated persons who are exposed to blodo or body fluids
that contain blood
Cause    Action
Discrete exposure to an HBsAg*-positive source
Percutaneous (e.g., bite, needlestick) or mucosal exposure to HBsAg-positive
blood or body fluids that contain blood
Sexual or needle-sharing contact of an HBsAg-positive person
Victim of sexual assault/abuse by a perpetrator who is HBsAg-positive
Discrete exposure to a source with unknown HBsAg status
Victim of sexual assault/abuse by a perpetrator with unknown HBsAg status
Percutaneous (e.g., bite or needclestick) or mucosal exposure to blood or
body fluids that contain blood from a source with unknown HBsAg status
* Hepatitis B surface antigen.
† Immunoprophylaxis should be administered as soon as possible, preferably <24 hours. Studies are limited on the maximum interval after exposure during
which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures and 14 days for sexual exposures. The
hepatitis B vaccine series should be completed.
Administer hepatitis B vaccine and hepatitis B immune globulin
(HBIG)†
Administer hepatitis B vaccine and HBIG†
Administer hepatitis B vaccine and HBIG†
Administer hepatitis B vaccine†
Administer hepatitis B vaccine†
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Glossary
Terms and Abbreviations Used in This Report
ACIP Advisory Committee on Immunization Practices
ALT alanine aminotransferase
Anti-HBc antibody to hepatitis B core antigen
Anti-HBe antibody to hepatitis B e antigen
Anti-HBs antibody to hepatitis B surface antigen
DTaP diphtheria and tetanus toxoids and acellular pertussis adsorbed
FDA Food and Drug Administration
HBcAg hepatitis B core antigen
HBeAg hepatitis B e antigen
HBIG hepatitis B immune globulin
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus
Hib Haemophilus influenzae type b




NHANES National Health and Nutrition Examination Survey
VAERS Vaccine Adverse Events Reporting System
VSD Vaccine Safety Datalink
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Goal and Objectives
This report updates the immunization strategy to eliminate hepatitis B virus (HBV) transmission in the United States. The report includes new recommendations and
implementation strategies for immunization of infants, children, and adolescents. The goal of the report is to provide guidance for health-care professionals to implement
these recommendations and strategies to prevent perinatal HBV transmission, to promote universal vaccination of infants as part of the routine childhood vaccination
schedule, and to promote vaccination of children and adolescents who were not previously vaccinated. Upon completion of this educational activity, the reader should
be able to a) identify ways to maintain high hepatitis B surface antigen (HBsAg) screening rates among pregnant women, b) describe the components of a case management
program for HBsAg-positive women, c) describe methods to ensure that newborn infants of HBsAg-positive mothers and mothers with unknown HBsAg status receive
appropriate immunoprophylaxis, d) describe how to structure programs to increase the number of infants who receive a birth dose of hepatitis B vaccine, e) list ways to
increase vaccine coverage among adolescents, and f) identify ways to increase rates of HBsAg screening and hepatitis B vaccination of foreign-born persons.
To receive continuing education credit, please answer all of the following questions.
1. Components of a health department case-management program to
enhance prevention of perinatal hepatitis B virus (HBV) infection
should ensure that…(Indicate all that apply.)
A. all pregnant women are tested for HBsAg.
B. HBsAg-positive women are reported and tracked.
C. prenatal HBsAg testing records are received by maternity hospitals
before delivery.
D. infants born to HBsAg-positive mothers and infants born to mothers
with unknown HBsAg status are identified and managed.
E. all of the above.
2. All delivery hospitals should implement standing orders for
administration of hepatitis B vaccination before hospital discharge as
part of routine medical care to all medically stable infants weighing
>2,000 g at birth. (Choose the one correct answer.)
A. True.
B. False
3. Which of the following statement(s) regarding HBsAg screening and
vaccination of immigrants and international adoptees is true? (Indicate
all that apply.)
A. All foreign-born persons (including immigrants, refugees, asylum
seekers, and internationally adopted children) from Asia, the Pacific
Islands, and Africa and other countries with HBsAg prevalence >2%
should be tested for HBsAg.
B. Persons who test positive for HBsAg should receive appropriate follow-
up, including counseling, evaluation for chronic liver disease and
antiviral treatment, and vaccination of susceptible household and
sexual contacts.
C. Persons who reside in the United States but who were vaccinated in
other countries should be considered fully vaccinated if they have
written documentation of at least three doses of vaccine administered
at recommended minimum intervals.
D. All of the above.
4. Identify health-care settings in which hepatitis B vaccine should be
offered to all unvaccinated adolescents. (Indicate all that apply.)
A. Drug treatment facilities.
B. Institutions for the developmentally disabled.
C. College health clinics.
D. Family planning clinics.
E. All of the above.
5. Which of the following statements regarding the hepatitis B vaccination
schedule in infants and children are true? (Indicate all that apply.)
A. Administration of the final dose to infants is not recommended before
age 24 weeks.
B. A vaccine series started with a birth dose of single-antigen vaccine
cannot be completed with 3 doses of combination vaccine.
C. No differences in immunogenicity have been observed when one or
two doses of hepatitis B vaccine produced by one manufacturer are
followed by dose(s) from a different manufacturer.
D. Currently licensed formulations for both single-antigen vaccines have
been demonstrated to produce high (>95%) levels of seroprotection
among infants, children, and adolescents when administered in
different schedules.
E. All of the above.
6. Which of the following statements regarding the management of
perinatal HBV exposure are true? (Indicate all that apply.)
A. Passive-active prophylaxis with hepatitis B vaccine and HBIG should
be administered within 12 hours after birth.
B. A vaccine series started with a birth dose of single-antigen vaccine can
be completed with three doses of combination vaccine.
C. Active postexposure prophylaxis with hepatitis B vaccine alone (i.e.,
without HBIG) beginning at birth is frequently used in areas where
implementation of maternal HBsAg testing is difficult (e.g., in Alaska,
Pacific Islands, and developing countries).
D. Although rates of perinatal HBV transmission are higher from HBeAg-
positive mothers compared with HBeAg-negative mothers, testing of
HBsAg-positive pregnant women for HBeAg is not warranted for the
management of the infant because postexposure prophylaxis is
recommended for all infants born to HBsAg-positive women.
E. All of the above.






8. I plan to use these recommendations as the basis for…(Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
9. Overall, the length of the journal report was…
A. much too long.
B. a little too long.
C. just right.
D. a little too short.
E. much too short.
10. After reading this report, I am confident I can identify ways to







11. After reading this report, I am confident I can describe the components





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































12. After reading this report, I am confident I can describe methods to
ensure that newborn infants of HBsAg-positive mothers and mothers






13. After reading this report, I am confident I can describe how to structure














15. After reading this report, I am confident I can identify ways to increase rates













17. The instructional strategies used in this report (text, tables, figures,
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Correct answers for questions 1–6.
1. E; 2. A; 3. D; 4. E; 5. A, C, and D; 6. E.


















22. The availability of continuing education credit influenced my












24. Do you feel this course was commercially biased? (Indicate yes or no;
if yes, please explain in the space provided.)
A. Yes.
B. No.
25. How did you learn about the continuing education activity?
A. Internet.
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